Figure 2.
Some disease features differ between OHI+ and OHI− patients. Bar plots comparing OHI+ (sCD25 >3900 U/mL and ferritin >1000 ng/mL) and OHI− patients in terms of Ann Arbor stage (A); ECOG scores (B); extranodal sites (C); the lymphoma-relevant prognostic indexes (D); extranodal sites location as defined by positron emission tomography-computed tomography scan or bone marrow biopsy (E); bone marrow involvement (F); COO (G); genetic alterations (H); and B symptoms (I). Disease features were compared using the χ2 test. ∗P < .05; ∗∗P < .01; ∗∗∗P < .001; ∗∗∗∗P < .0001. CNS, central nervous system; DH/TH, double hit/triple hit lymphoma; NA, not available; ns, nonsignificant.

Some disease features differ between OHI+ and OHI− patients. Bar plots comparing OHI+ (sCD25 >3900 U/mL and ferritin >1000 ng/mL) and OHI− patients in terms of Ann Arbor stage (A); ECOG scores (B); extranodal sites (C); the lymphoma-relevant prognostic indexes (D); extranodal sites location as defined by positron emission tomography-computed tomography scan or bone marrow biopsy (E); bone marrow involvement (F); COO (G); genetic alterations (H); and B symptoms (I). Disease features were compared using the χ2 test. ∗P < .05; ∗∗P < .01; ∗∗∗P < .001; ∗∗∗∗P < .0001. CNS, central nervous system; DH/TH, double hit/triple hit lymphoma; NA, not available; ns, nonsignificant.

This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal